Consensus of the Brazilian Headache Society (SBCe) for prophylactic treatment of episodic migraine: part II
Authors:
- Paulo Sergio Faro SantosPSPaulo Sergio Faro Santos
- Eliana Meire MelhadoEMEliana Meire Melhado
- Alexandre Ottoni KaupAKAlexandre Ottoni Kaup
- Aline Turbino Neves Martins da CostaACAline Turbino Neves Martins da Costa
- Célia Aparecida de Paula RoeslerCRCélia Aparecida de Paula Roesler
- Élcio Juliato PiovesanÉPÉlcio Juliato Piovesan
- Elder Machado SarmentoESElder Machado Sarmento
- Giselle Oliveira Martins TheotonioGTGiselle Oliveira Martins Theotonio
- Henrique Carneiro de CamposHCHenrique Carneiro de Campos
- Ida FortiniIFIda Fortini
- Jano Alves de SouzaJSJano Alves de Souza
- Jayme Antunes Maciel JúniorJJJayme Antunes Maciel Júnior
Open Access
- 1 September 2022
- journal article
- research article
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 80 (09) , 953-969
Abstract
Background Migraine affects 1 billion people worldwide and > 30 million Brazilians; besides, it is an underdiagnosed and undertreated disorder.Objective The need to disseminate knowledge about the prophylactic treatment of migraine is known, so the Brazilian Headache Society (SBCe, in the Portuguese acronym) appointed a committee of authors with the objective of establishing a consensus with recommendations on the prophylactic treatment of episodic migraine based on articles from the world literature as well as from personal experience.Methods Meetings were held entirely online, with the participation of 12 groups that reviewed and wrote about the pharmacological categories of drugs and, at the end, met to read and finish the document. The drug classes studied in part II of this Consensus were: antihypertensives, selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, calcium channel blockers, other drugs, and rational polytherapy.Results From this list of drugs, only candesartan has been established as effective in controlling episodic migraine. Flunarizine, venlafaxine, duloxetine, and pizotifen were defined as likely to be effective, while lisinopril, enalapril, escitalopram, fluvoxamine, quetiapine, atorvastatin, simvastatin, cyproheptadine, and melatonin were possibly effective in prophylaxis of the disease.Conclusions Despite an effort by the scientific community to find really effective drugs in the treatment of migraine, given the large number of drugs tested for this purpose, we still have few therapeutic options.Keywords
This publication has 143 references indexed in Scilit:
- Duloxetine Prophylaxis for Episodic Migraine in Persons Without Depression: A Prospective StudyHeadache: The Journal of Head and Face Pain, 2013
- An unusual case report on the possible role of Warfarin in migraine prophylaxisSpringerPlus, 2013
- Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonrespondersThe Journal of Headache and Pain, 2011
- Protection of flunarizine on cerebral mitochondria injury induced by cortical spreading depression under hypoxic conditionsThe Journal of Headache and Pain, 2011
- Angiotensin-converting enzyme gene insertion/deletion polymorphism in migraine patientsBMC Neurology, 2008
- Is It Worthwhile to Test Statin in Migraine?Headache: The Journal of Head and Face Pain, 2007
- PLEIOTROPIC EFFECTS OF STATINSAnnual Review of Pharmacology and Toxicology, 2005
- Warfarin treatment and migraine1994
- Efficacy of Nimodipine in Comparison with Pizotifen in the Prophylaxis of MigraineCephalalgia, 1987
- Metoprolol and Pizotifen in The Prophylactic Treatment of Classical and Common Migraine. A Double-Blind InvestigationCephalalgia, 1985